This book focuses on early diagnosis and multidisciplinary treatment, which is the key to preventing the occurrence of the liver metastases in colorectal cancer, and to increasing the resection rate of the liver metastasis foci and the 5-year survival after surgery. This book is divided into five parts: the introduction, basics, diagnosis, treatment and prevention. It has 20 chapters in total, covering the latest advances in colorectal cancer liver metastases epidemiology, pathogenesis, molecular diagnostics, marker screening, imaging technology, surgery, chemotherapy and prevention, etc. It provides professionals with up-to-date and comprehensive information on colorectal liver metastases. This book is relevant for senior surgeons and physicians working in oncology, general surgery, chemotherapy, digestive medicine, liver medicine and hepatic surgery.
This book addresses the contemporary multidisciplinary management of liver metastases. Throughout the text, experience from the paradigms of colorectal cancer metastases treatment strategies are used to point to new directions in the management of liver metastases from other cancers. The book will be invaluable for surgeons in general surgery, hepatobiliary surgery, upper GI surgery, colorectal surgery, medical and clinical oncologists with an interest in liver tumours, and radiologists with an interest in liver disease.
Surgery is the gold standard treatment of colorectal liver metastases. Patients management had a dramatic evolution during the past years: more accurate diagnostic tools and more effective chemotherapy regimens have been introduced and surgical indications have been widely broadened. A multidisciplinary treatment is now mandatory, involving oncologists, radiologists an gastroenterologists. However, many topics are still debated. In the present book all aspects of surgical treatment of colorectal liver metastases are analyzed based on a systematic, updated analysis of the literature. Aim of this book is to provide surgeons, oncologists and radiologists a clear overview of the state-of-the-art of treatment of colorectal liver metastases.
Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.
Liver Metastasis: Biology, Diagnosis and Treatment offers a comprehensive overview of liver metastasis by providing a collection of pivotal contributions from an international faculty. A wide range of topics are presented, with each contributor focusing on his own area of expertise to provide the latest techniques as well as valuable insights based on a wealth of experience. Epidemiological and biological aspects are discussed, diagnostic and staging problems are reported, and all treatment modalities are analysed including gene therapy, immunotherapy and palliative care. The standard approaches to diagnosis and therapy are examined whilst new and future trends are reported on and explored. Of interest to both specialists and postgraduates in the fields of oncology and gastroenterology this book will also be of interest to researchers in internal medicine.
This book seeks to promote an integrated approach among the various specialists involved in the management of rectal cancer with a view to ensuring that treatment is tailored appropriately to the individual patient. For ease of use, a question and answer format is employed. The focus is on those issues typically confronted during daily clinical practice in relation to risk factors, imaging, surgery, radiotherapy, and chemotherapy. The services of an outstanding panel of authors representative of the major European oncological societies have been acquired in order to formulate the questions and provide the answers. All who need assistance in addressing concerns that arise from the need for multidisciplinary management of rectal cancer will find the book to be an ideal source of helpful information.
Colorectal cancer is the third most commonly diagnosed condition in oncology, affecting around 1.23 million individuals per year, according to recent statistics. Of these patients, about 50% will develop liver metastases and approximately 20% will present a stage IV disease at diagnosis. These statistics make colorectal liver metastases (CLM) an issue of major importance in current oncology. The area of CLM is subject to great and continuous advances, as its pathophysiologic mechanisms are better understood and more therapeutic and surgical options are developed. Consequently, all professionals involved with the diagnosis, treatment and follow up of CLM should be kept up to date with the latest advances on the field, to provide high standard medical care to their patients. This book is designed to present the state-of-the-art in CLM management and, in doing so, to review the current evidence on CLM, discussing all important topics in the field. Coverage is broad and comprehensive, encompassing introductory topics (history, definitions, epidemiology, etc.), basic science subjects (molecular biology, genetics, dissemination process, etc.) and practical clinical topics (tumor behavior, diagnosis, drug therapy, radiation therapy, surgery, ablation, multidisciplinary teams, etc.). Although comprehensive on the coverage and selection of topics, each chapter is concise and objective, dissecting topics in a practical and direct format. Evidences and recommendations are included. Chapters display a brief introduction of the common knowledge, go straight to the detailed revision of the most recent years of the literature, and end with practical closing observations. This book is a tool for professionals (general and cancer surgeons, HPB surgeons, clinical oncologists, gastroenterologists and medical residents) and interns who search for a qualified and reader friendly revision on topics concerning Colorectal Cancer Liver Metastases.
This book provides a practically applicable guide to the management of liver metastases in cases of colorectal cancer. It features detailed reviews of the latest diagnostic and therapeutic options. Instruction on how to appropriately apply surgical techniques including two stage hepatectomy as well as both laprascopic and open resection in a variety of scenarios is covered. The use of systemic therapies involving oxaliplatin, immunotherapy and infusional therapy are also described along with a range of surveillance strategies. Vauthey and Adam Colorectal Liver Metastasis comprehensively covers the latest advances in how to successfully diagnose and treat colorectal liver metastases and is an indispensable resource for all trainee and practicing medical professionals who encounter these patients within their clinical practice.
Colorectal cancer Colorectal cancer is the third most common malignant tumor worldwide. Globally, more than 600.000 people die from colorectal cancer every year, mainly from metastatic disease. Before the era of chemotherapy, patients with mCRC had a median overall survival of 9 months. With the introduction chemotherapeutic agents and targeted agents against VEGF and the EGF receptor, overall survival has improved to over 30 months. Originally, when patients presented with metastases, the disease was viewed as always being widespread and patients have typically been treated with systemic therapy. However, local treatment of metastases is technically feasible in an increasing number of patients with mCRC by either resection, radiofrequency ablation or stereotactic radiotherapy. Preliminary and retrospective evidence suggests that patients with extensive multi-organ mCRC may benefit from local treatment of metastases. This results in a growing debate in multidisciplinary teams on whether local treatment of metastases should be performed in these patients. Part One: Debulking in metastatic colorectal cancer In Chapter 2, the rationale of debulking therapy for patients with multi-organ mCRC is reviewed. The ORCHESTRA trial is the first multicenter randomized clinical trial in which is evaluated if multidisciplinary local treatment in addition to first line palliative systemic treatment (NCT01792934) results in survival benefit for patients with extensive mCRC. A preplanned safety and feasibility evaluation was performed aftercompletion of study treatment of the first 100 patients enrolled in the trial and reported in Chapter 3. A translational study program was embedded in the ORCHESTRA trial protocol and blood and tissue samples were collected from all patients enrolled.
